Skip to content

Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy

Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02875717
Enrollment
500
Registered
2016-08-23
Start date
2009-01-31
Completion date
2015-09-30
Last updated
2016-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Hematoma, Urolithiasis

Brief summary

Retrospective Analysis of patients that received shockwave lithotripsy as Treatment of ureteral or kidney Stones. Condition examinated is the effect of low molecular weight Heparins and acetylsalicylic acid on the Formation of renal hematoma after shockwave lithotripsy. Primary outcome is documented hematoma in a postoperative ultrasound control. Secondary outcomes are perioperative complication, Need for erythrocyte tranfusion, interventions for bleeding control, readmission or death within 30 days.

Interventions

DRUGAcetylsalicylic acid
DRUGlow molecular weight heparin

Sponsors

Kantonsspital Winterthur KSW
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* consent * Stones in kidney and proximal Ureter * Treatment with shockwave lithotripsy for urolithiasis between January 2009 and September 2015 at Kantonsspital Winterthur

Exclusion criteria

* other Position of ureteral Stones * missing data in Patient reports * refused consent * under Age limit

Design outcomes

Primary

MeasureTime frame
Renal Hematoma in ultrasound controlfirst day after intervention

Secondary

MeasureTime frame
Intervention for bleeding control30 days after intervention
Need for erythrocyte concentrate tranfusion30 days after intervention
Death30 days after intervention
Hospital readmission30 days after intervention

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026